Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01765400 · ClinicalTrials.gov registry record · Phase 4

Platelet Inhibition in Patients With Systolic Heart Failure

A Phase 4 study of Systolic Heart Failure, sponsored by University of Nebraska.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT01765400: Completed Phase 4 study of Systolic Heart Failure, sponsored by University of Nebraska.

NCT01765400 is a Phase 4 study of Systolic Heart Failure that has completed, run by University of Nebraska. The registered enrollment target is 30 participants, below the 126-participant average among 3 other Systolic Heart Failure trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01765400, a Phase 4 study of Systolic Heart Failure, has completed, sponsored by University of Nebraska.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The investigators aim to determine if patients with systolic heart failure treated with prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.

Conditions Studied

Interventions

  • DRUG Prasugrel 10 mg daily x 2 weeks
  • DRUG Clopidogrel 75 mg daily x 2 weeks

Study Locations (1)

Nebraska

  • University of Nebaska Medical Center - Omaha

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-05-15
Est. Completion 2015-12-28
Phase Phase 4
University of Nebraska

407 total trials

What the finished NCT01765400 record still lists

NCT01765400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 126-participant average among 3 other Systolic Heart Failure trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Systolic Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Prasugrel 10 mg daily x 2 weeks is the first listed.

NCT01765400 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT01765400 about?

NCT01765400 is a clinical study titled "Platelet Inhibition in Patients With Systolic Heart Failure". The investigators aim to determine if patients with systolic heart failure treated with prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.

What is the current status of trial NCT01765400?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2013-05-15. Estimated completion is 2015-12-28.

What conditions does trial NCT01765400 study?

This clinical trial studies the following conditions: Systolic Heart Failure.

What interventions are being tested in trial NCT01765400?

The interventions under investigation include: Prasugrel 10 mg daily x 2 weeks (DRUG), Clopidogrel 75 mg daily x 2 weeks (DRUG).

Who is sponsoring clinical trial NCT01765400?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01765400 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Systolic Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01765400, the US trial registry maintained by the National Library of Medicine. NCT01765400 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.